Nikita Pozdeyev
Concepts (345)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 18 | 2026 | 350 | 5.020 |
Why?
| | Thyroid Nodule | 3 | 2026 | 57 | 2.510 |
Why?
| | Thyroid Carcinoma, Anaplastic | 4 | 2020 | 36 | 1.410 |
Why?
| | Artificial Intelligence | 2 | 2026 | 381 | 1.320 |
Why?
| | Retina | 13 | 2012 | 326 | 1.040 |
Why?
| | Adrenal Cortex Neoplasms | 3 | 2026 | 70 | 0.990 |
Why?
| | Adrenocortical Carcinoma | 3 | 2026 | 72 | 0.990 |
Why?
| | Multiple Endocrine Neoplasia Type 2a | 1 | 2025 | 14 | 0.920 |
Why?
| | Thyroid Diseases | 1 | 2026 | 44 | 0.920 |
Why?
| | Hamartoma Syndrome, Multiple | 1 | 2025 | 16 | 0.920 |
Why?
| | Thyroid Gland | 1 | 2026 | 89 | 0.910 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2025 | 40 | 0.900 |
Why?
| | Carcinoma | 1 | 2025 | 225 | 0.770 |
Why?
| | Thyroxine | 1 | 2023 | 66 | 0.760 |
Why?
| | Hypothyroidism | 1 | 2023 | 67 | 0.750 |
Why?
| | Adenoma | 1 | 2025 | 218 | 0.740 |
Why?
| | Melatonin | 9 | 2009 | 163 | 0.740 |
Why?
| | Dopamine | 11 | 2018 | 295 | 0.730 |
Why?
| | Circadian Rhythm | 10 | 2011 | 512 | 0.700 |
Why?
| | Proto-Oncogene Proteins B-raf | 6 | 2023 | 223 | 0.690 |
Why?
| | Genome-Wide Association Study | 4 | 2026 | 1407 | 0.690 |
Why?
| | Ultrasonography | 4 | 2026 | 785 | 0.670 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2020 | 36 | 0.610 |
Why?
| | Splenectomy | 1 | 2020 | 61 | 0.610 |
Why?
| | Bacterial Vaccines | 1 | 2020 | 63 | 0.600 |
Why?
| | Biomarkers, Tumor | 5 | 2024 | 1321 | 0.570 |
Why?
| | Antigens, Neoplasm | 1 | 2020 | 271 | 0.550 |
Why?
| | Pharmacogenomic Testing | 1 | 2016 | 63 | 0.470 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2021 | 881 | 0.450 |
Why?
| | Guideline Adherence | 1 | 2020 | 586 | 0.440 |
Why?
| | Databases, Genetic | 1 | 2016 | 238 | 0.440 |
Why?
| | NF-kappa B | 2 | 2015 | 666 | 0.420 |
Why?
| | Antineoplastic Agents | 2 | 2016 | 2214 | 0.420 |
Why?
| | Data Collection | 1 | 2016 | 640 | 0.390 |
Why?
| | Photoreceptor Cells, Vertebrate | 3 | 2012 | 29 | 0.390 |
Why?
| | Mutation | 9 | 2021 | 4075 | 0.390 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2024 | 1149 | 0.390 |
Why?
| | Sepsis | 1 | 2020 | 664 | 0.390 |
Why?
| | Genetic Predisposition to Disease | 3 | 2026 | 2378 | 0.380 |
Why?
| | Genetic Variation | 1 | 2018 | 972 | 0.380 |
Why?
| | Thyroidectomy | 3 | 2024 | 92 | 0.360 |
Why?
| | Photoreceptor Cells | 3 | 2008 | 18 | 0.350 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1581 | 0.350 |
Why?
| | Genomics | 4 | 2024 | 825 | 0.340 |
Why?
| | Humans | 35 | 2026 | 145475 | 0.340 |
Why?
| | Eye Proteins | 3 | 2008 | 92 | 0.300 |
Why?
| | Adenocarcinoma, Follicular | 2 | 2019 | 40 | 0.290 |
Why?
| | Cell Line, Tumor | 9 | 2026 | 3542 | 0.290 |
Why?
| | Signal Transduction | 4 | 2018 | 5216 | 0.290 |
Why?
| | GTP-Binding Protein Regulators | 1 | 2008 | 2 | 0.280 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2021 | 212 | 0.270 |
Why?
| | Arylalkylamine N-Acetyltransferase | 2 | 2006 | 2 | 0.260 |
Why?
| | 14-3-3 Proteins | 1 | 2006 | 15 | 0.250 |
Why?
| | Chile | 1 | 2026 | 27 | 0.240 |
Why?
| | Hospitals, Public | 1 | 2026 | 30 | 0.240 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2026 | 2158 | 0.240 |
Why?
| | Biopsy, Fine-Needle | 1 | 2026 | 68 | 0.240 |
Why?
| | Genetic Heterogeneity | 1 | 2026 | 66 | 0.230 |
Why?
| | Protein Kinase Inhibitors | 4 | 2026 | 981 | 0.230 |
Why?
| | Phosphoproteins | 1 | 2008 | 337 | 0.230 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2025 | 41 | 0.230 |
Why?
| | 3,4-Dihydroxyphenylacetic Acid | 7 | 2011 | 20 | 0.220 |
Why?
| | United Kingdom | 1 | 2025 | 344 | 0.210 |
Why?
| | Thyroglobulin | 1 | 2024 | 29 | 0.210 |
Why?
| | PTEN Phosphohydrolase | 1 | 2025 | 165 | 0.210 |
Why?
| | Retrospective Studies | 5 | 2026 | 17291 | 0.210 |
Why?
| | MAP Kinase Signaling System | 2 | 2023 | 307 | 0.210 |
Why?
| | Cross-Sectional Studies | 2 | 2026 | 5905 | 0.210 |
Why?
| | Multifactorial Inheritance | 1 | 2025 | 195 | 0.200 |
Why?
| | Kynuramine | 1 | 2003 | 1 | 0.200 |
Why?
| | Lighting | 2 | 2000 | 31 | 0.200 |
Why?
| | Biological Clocks | 4 | 2008 | 48 | 0.200 |
Why?
| | Computers | 1 | 2023 | 66 | 0.190 |
Why?
| | Dopamine Agents | 2 | 2018 | 22 | 0.190 |
Why?
| | Levodopa | 2 | 2018 | 40 | 0.190 |
Why?
| | Thyrotropin | 1 | 2023 | 120 | 0.190 |
Why?
| | Neoplasm Staging | 2 | 2018 | 1471 | 0.180 |
Why?
| | Middle Aged | 8 | 2026 | 36215 | 0.180 |
Why?
| | Data Warehousing | 1 | 2022 | 5 | 0.180 |
Why?
| | Cloud Computing | 1 | 2022 | 6 | 0.180 |
Why?
| | Models, Genetic | 1 | 2025 | 524 | 0.180 |
Why?
| | Light | 4 | 2009 | 403 | 0.170 |
Why?
| | Retinal Rod Photoreceptor Cells | 3 | 2018 | 17 | 0.170 |
Why?
| | Gene Frequency | 2 | 2025 | 487 | 0.170 |
Why?
| | Reoperation | 1 | 2024 | 633 | 0.170 |
Why?
| | Immunohistochemistry | 5 | 2020 | 1716 | 0.170 |
Why?
| | Female | 14 | 2026 | 78845 | 0.160 |
Why?
| | Receptor, Melatonin, MT1 | 2 | 2011 | 6 | 0.160 |
Why?
| | Neoplasms | 1 | 2016 | 2906 | 0.160 |
Why?
| | Aged | 6 | 2026 | 26153 | 0.160 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2021 | 135 | 0.160 |
Why?
| | Diagnosis, Differential | 1 | 2025 | 1508 | 0.160 |
Why?
| | MutS Homolog 2 Protein | 1 | 2020 | 12 | 0.160 |
Why?
| | Animals | 26 | 2026 | 38030 | 0.160 |
Why?
| | Night Blindness | 2 | 2012 | 6 | 0.160 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2020 | 16 | 0.160 |
Why?
| | Pheochromocytoma | 1 | 2021 | 67 | 0.160 |
Why?
| | Male | 16 | 2026 | 72843 | 0.160 |
Why?
| | Calcitonin | 1 | 2020 | 27 | 0.160 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2021 | 171 | 0.160 |
Why?
| | Paraganglioma | 1 | 2021 | 64 | 0.160 |
Why?
| | Trans-Activators | 2 | 2021 | 396 | 0.150 |
Why?
| | Haemophilus influenzae type b | 1 | 2020 | 12 | 0.150 |
Why?
| | Neisseria meningitidis | 1 | 2020 | 23 | 0.150 |
Why?
| | Organizational Case Studies | 1 | 2020 | 69 | 0.150 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2026 | 534 | 0.150 |
Why?
| | Receptors, Virus | 1 | 2020 | 95 | 0.150 |
Why?
| | Tyrosine | 1 | 2000 | 217 | 0.150 |
Why?
| | Myopia | 2 | 2012 | 59 | 0.150 |
Why?
| | Disease Susceptibility | 2 | 2020 | 344 | 0.150 |
Why?
| | Neuroendocrine Tumors | 1 | 2021 | 119 | 0.150 |
Why?
| | Software | 1 | 2025 | 680 | 0.150 |
Why?
| | Precision Medicine | 1 | 2024 | 459 | 0.150 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2021 | 1443 | 0.150 |
Why?
| | Cell Proliferation | 4 | 2026 | 2507 | 0.150 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2020 | 174 | 0.140 |
Why?
| | DNA Mutational Analysis | 1 | 2020 | 407 | 0.140 |
Why?
| | Crk-Associated Substrate Protein | 1 | 2018 | 4 | 0.140 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1997 | 0.140 |
Why?
| | Immune System | 1 | 2020 | 180 | 0.140 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2018 | 32 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2018 | 54 | 0.140 |
Why?
| | Leukocytes | 1 | 2020 | 296 | 0.140 |
Why?
| | Prevalence | 1 | 2025 | 2865 | 0.140 |
Why?
| | src-Family Kinases | 1 | 2018 | 92 | 0.140 |
Why?
| | Pharmacogenomic Variants | 1 | 2018 | 35 | 0.130 |
Why?
| | DNA Mismatch Repair | 1 | 2018 | 53 | 0.130 |
Why?
| | Adrenal Cortex | 1 | 2018 | 33 | 0.130 |
Why?
| | Streptococcus pneumoniae | 1 | 2020 | 184 | 0.130 |
Why?
| | Rod Opsins | 2 | 2009 | 7 | 0.130 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 254 | 0.130 |
Why?
| | Oncogenes | 1 | 2018 | 118 | 0.130 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 41 | 0.130 |
Why?
| | Mice | 14 | 2026 | 18329 | 0.130 |
Why?
| | Dark Adaptation | 3 | 2018 | 13 | 0.130 |
Why?
| | Neoplasm Grading | 1 | 2018 | 310 | 0.130 |
Why?
| | Postoperative Complications | 2 | 2023 | 2970 | 0.120 |
Why?
| | Adult | 5 | 2026 | 40777 | 0.120 |
Why?
| | Telomerase | 1 | 2019 | 246 | 0.120 |
Why?
| | United States | 3 | 2025 | 16098 | 0.120 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2018 | 199 | 0.120 |
Why?
| | Electroretinography | 5 | 2018 | 50 | 0.120 |
Why?
| | Photic Stimulation | 2 | 2008 | 263 | 0.120 |
Why?
| | Combined Modality Therapy | 2 | 2018 | 1266 | 0.120 |
Why?
| | Amino Acids | 1 | 2000 | 519 | 0.120 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1767 | 0.120 |
Why?
| | Caspase 7 | 1 | 2015 | 22 | 0.110 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2019 | 431 | 0.110 |
Why?
| | Tyrosine 3-Monooxygenase | 3 | 2018 | 72 | 0.110 |
Why?
| | Tumor Suppressor Proteins | 1 | 2018 | 321 | 0.110 |
Why?
| | Disease Management | 1 | 2020 | 653 | 0.110 |
Why?
| | Bortezomib | 1 | 2015 | 54 | 0.110 |
Why?
| | Inhibitory Concentration 50 | 1 | 2015 | 90 | 0.110 |
Why?
| | Information Storage and Retrieval | 1 | 2016 | 123 | 0.110 |
Why?
| | User-Computer Interface | 1 | 2016 | 165 | 0.110 |
Why?
| | Hypocalcemia | 1 | 2015 | 39 | 0.110 |
Why?
| | Diabetic Retinopathy | 1 | 2018 | 209 | 0.110 |
Why?
| | Taxoids | 1 | 2015 | 114 | 0.110 |
Why?
| | Disease Progression | 2 | 2020 | 2864 | 0.110 |
Why?
| | Radiation, Ionizing | 1 | 2015 | 86 | 0.110 |
Why?
| | Pharmacogenetics | 1 | 2016 | 175 | 0.110 |
Why?
| | Genetic Testing | 1 | 2018 | 480 | 0.110 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1061 | 0.110 |
Why?
| | Mice, Knockout | 6 | 2018 | 3124 | 0.110 |
Why?
| | Caspase 3 | 1 | 2015 | 242 | 0.110 |
Why?
| | Prognosis | 2 | 2024 | 4316 | 0.100 |
Why?
| | Cell Death | 1 | 2015 | 382 | 0.100 |
Why?
| | Apoptosis | 4 | 2026 | 2440 | 0.100 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1246 | 0.100 |
Why?
| | Computational Biology | 1 | 2018 | 669 | 0.100 |
Why?
| | Interleukin-8 | 1 | 2014 | 269 | 0.100 |
Why?
| | Phosphorylation | 2 | 2008 | 1707 | 0.090 |
Why?
| | Rats | 6 | 2010 | 5584 | 0.090 |
Why?
| | Neoplasm Transplantation | 3 | 2019 | 246 | 0.090 |
Why?
| | Neovascularization, Pathologic | 1 | 2014 | 286 | 0.090 |
Why?
| | Models, Biological | 1 | 2020 | 1764 | 0.090 |
Why?
| | Molecular Targeted Therapy | 1 | 2015 | 439 | 0.090 |
Why?
| | Macrophages | 1 | 2020 | 1507 | 0.090 |
Why?
| | Retinal Bipolar Cells | 1 | 2012 | 7 | 0.090 |
Why?
| | Mice, Nude | 3 | 2021 | 679 | 0.090 |
Why?
| | Gene Expression Regulation | 3 | 2012 | 2597 | 0.090 |
Why?
| | Calcium | 2 | 2015 | 1190 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1963 | 0.080 |
Why?
| | Dopamine Agonists | 2 | 2008 | 41 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2025 | 2588 | 0.080 |
Why?
| | Dopamine beta-Hydroxylase | 1 | 2010 | 13 | 0.080 |
Why?
| | Rats, Wistar | 3 | 2001 | 450 | 0.080 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2026 | 934 | 0.080 |
Why?
| | Disulfiram | 1 | 2010 | 15 | 0.080 |
Why?
| | Homovanillic Acid | 2 | 2000 | 10 | 0.080 |
Why?
| | Alcohol Deterrents | 1 | 2010 | 26 | 0.080 |
Why?
| | Conditioning, Operant | 1 | 2010 | 94 | 0.080 |
Why?
| | Algorithms | 1 | 2018 | 1845 | 0.080 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2012 | 231 | 0.080 |
Why?
| | Mice, Inbred C57BL | 5 | 2018 | 5983 | 0.070 |
Why?
| | Chickens | 2 | 2006 | 179 | 0.070 |
Why?
| | Obesity | 1 | 2023 | 3116 | 0.070 |
Why?
| | Vision, Ocular | 1 | 2009 | 47 | 0.070 |
Why?
| | Extinction, Psychological | 1 | 2010 | 92 | 0.070 |
Why?
| | Light Signal Transduction | 1 | 2009 | 7 | 0.070 |
Why?
| | Amacrine Cells | 1 | 2009 | 13 | 0.070 |
Why?
| | Cyclic AMP | 2 | 2006 | 207 | 0.070 |
Why?
| | Cocaine | 1 | 2010 | 161 | 0.070 |
Why?
| | Dopamine Antagonists | 1 | 2008 | 26 | 0.070 |
Why?
| | Receptors, Dopamine D4 | 1 | 2008 | 27 | 0.070 |
Why?
| | Cells, Cultured | 4 | 2014 | 4148 | 0.070 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 2011 | 592 | 0.070 |
Why?
| | Visual Pathways | 1 | 2008 | 61 | 0.070 |
Why?
| | Disease Models, Animal | 3 | 2019 | 4560 | 0.060 |
Why?
| | Retinal Diseases | 1 | 2008 | 101 | 0.060 |
Why?
| | Nerve Growth Factors | 1 | 2007 | 78 | 0.060 |
Why?
| | Mammals | 1 | 2008 | 286 | 0.060 |
Why?
| | Adenylyl Cyclases | 1 | 2006 | 60 | 0.060 |
Why?
| | Calmodulin | 1 | 2006 | 70 | 0.060 |
Why?
| | Darkness | 2 | 2009 | 26 | 0.060 |
Why?
| | Treatment Outcome | 4 | 2024 | 11772 | 0.060 |
Why?
| | RNA, Messenger | 6 | 2012 | 2803 | 0.060 |
Why?
| | Arylamine N-Acetyltransferase | 1 | 2005 | 8 | 0.060 |
Why?
| | Imidazoles | 2 | 2021 | 247 | 0.060 |
Why?
| | Neck Dissection | 1 | 2024 | 17 | 0.050 |
Why?
| | Enzyme Activation | 1 | 2006 | 762 | 0.050 |
Why?
| | Recurrent Laryngeal Nerve Injuries | 1 | 2024 | 16 | 0.050 |
Why?
| | Retinal Ganglion Cells | 1 | 2005 | 121 | 0.050 |
Why?
| | Early Growth Response Protein 1 | 1 | 2023 | 32 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2025 | 3623 | 0.050 |
Why?
| | Genetics, Population | 1 | 2025 | 217 | 0.050 |
Why?
| | Lymph Node Excision | 1 | 2024 | 173 | 0.050 |
Why?
| | DNA Damage | 1 | 2026 | 437 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2024 | 109 | 0.050 |
Why?
| | Fibronectins | 1 | 2023 | 136 | 0.050 |
Why?
| | Phenotype | 2 | 2023 | 3155 | 0.050 |
Why?
| | 1,2-Dimethylhydrazine | 1 | 2001 | 1 | 0.040 |
Why?
| | Median Eminence | 1 | 2001 | 5 | 0.040 |
Why?
| | Preoptic Area | 1 | 2001 | 8 | 0.040 |
Why?
| | Suprachiasmatic Nucleus | 1 | 2001 | 19 | 0.040 |
Why?
| | Biogenic Monoamines | 1 | 2001 | 17 | 0.040 |
Why?
| | Preoperative Care | 1 | 2024 | 380 | 0.040 |
Why?
| | Oximes | 1 | 2021 | 26 | 0.040 |
Why?
| | Retinal Degeneration | 2 | 2012 | 40 | 0.040 |
Why?
| | Carcinogens | 1 | 2001 | 123 | 0.040 |
Why?
| | Risk Assessment | 2 | 2024 | 3747 | 0.040 |
Why?
| | Indazoles | 1 | 2021 | 85 | 0.040 |
Why?
| | Models, Statistical | 1 | 2025 | 671 | 0.040 |
Why?
| | Computer Simulation | 1 | 2025 | 1003 | 0.040 |
Why?
| | Protein Binding | 1 | 2006 | 2238 | 0.040 |
Why?
| | Drug Synergism | 1 | 2021 | 354 | 0.040 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2021 | 98 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2003 | 1067 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 886 | 0.040 |
Why?
| | Validation Studies as Topic | 1 | 2019 | 23 | 0.040 |
Why?
| | Wnt Signaling Pathway | 1 | 2021 | 211 | 0.040 |
Why?
| | Dasatinib | 1 | 2018 | 58 | 0.030 |
Why?
| | Piperazines | 1 | 2021 | 375 | 0.030 |
Why?
| | Luminescence | 1 | 2018 | 37 | 0.030 |
Why?
| | Pineal Gland | 2 | 2012 | 15 | 0.030 |
Why?
| | Aldosterone | 1 | 2018 | 42 | 0.030 |
Why?
| | Cell Survival | 2 | 2012 | 1100 | 0.030 |
Why?
| | Neurons | 1 | 2007 | 1649 | 0.030 |
Why?
| | Oscillometry | 1 | 2018 | 35 | 0.030 |
Why?
| | Drug Interactions | 2 | 2010 | 405 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 176 | 0.030 |
Why?
| | Blotting, Western | 2 | 2011 | 1179 | 0.030 |
Why?
| | Chick Embryo | 2 | 2006 | 132 | 0.030 |
Why?
| | In Situ Hybridization | 2 | 2007 | 318 | 0.030 |
Why?
| | Norepinephrine | 2 | 2010 | 201 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 530 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2024 | 5423 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 1038 | 0.030 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2014 | 50 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 977 | 0.030 |
Why?
| | Cell Line | 1 | 2019 | 2823 | 0.030 |
Why?
| | I-kappa B Proteins | 1 | 2014 | 75 | 0.030 |
Why?
| | Colorado | 1 | 2024 | 4554 | 0.020 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2014 | 104 | 0.020 |
Why?
| | Body Weight | 1 | 2018 | 971 | 0.020 |
Why?
| | Mucoproteins | 1 | 2012 | 8 | 0.020 |
Why?
| | Opsins | 1 | 2012 | 8 | 0.020 |
Why?
| | Bromodeoxyuridine | 1 | 2012 | 77 | 0.020 |
Why?
| | Nerve Tissue Proteins | 2 | 2006 | 591 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2012 | 116 | 0.020 |
Why?
| | Oncogene Proteins | 1 | 2012 | 62 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2012 | 156 | 0.020 |
Why?
| | Eye Diseases, Hereditary | 1 | 2012 | 15 | 0.020 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2012 | 26 | 0.020 |
Why?
| | Receptors, Metabotropic Glutamate | 1 | 2012 | 37 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2012 | 254 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2014 | 688 | 0.020 |
Why?
| | Transcription Factors | 2 | 2012 | 1734 | 0.020 |
Why?
| | Risk Factors | 1 | 2025 | 10885 | 0.020 |
Why?
| | Heterozygote | 1 | 2012 | 313 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2012 | 333 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 2012 | 506 | 0.020 |
Why?
| | Thiones | 1 | 2010 | 13 | 0.020 |
Why?
| | Pedigree | 1 | 2012 | 515 | 0.020 |
Why?
| | Self Administration | 1 | 2010 | 122 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2012 | 1300 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2012 | 425 | 0.020 |
Why?
| | Adaptation, Biological | 1 | 2009 | 48 | 0.020 |
Why?
| | Food | 1 | 2010 | 150 | 0.020 |
Why?
| | Transducin | 1 | 2009 | 42 | 0.020 |
Why?
| | GTP-Binding Protein alpha Subunits | 1 | 2009 | 15 | 0.020 |
Why?
| | Retinal Cone Photoreceptor Cells | 1 | 2009 | 20 | 0.020 |
Why?
| | CLOCK Proteins | 1 | 2008 | 9 | 0.020 |
Why?
| | Periodicity | 1 | 2008 | 58 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2009 | 196 | 0.020 |
Why?
| | Feedback, Physiological | 1 | 2008 | 80 | 0.020 |
Why?
| | Sensory Deprivation | 1 | 2008 | 17 | 0.020 |
Why?
| | Young Adult | 1 | 2024 | 14219 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2008 | 302 | 0.020 |
Why?
| | Blood Glucose | 1 | 2018 | 2341 | 0.020 |
Why?
| | Proteoglycans | 1 | 2008 | 112 | 0.020 |
Why?
| | Zebrafish | 1 | 2012 | 532 | 0.020 |
Why?
| | Calcium Channel Agonists | 1 | 2006 | 12 | 0.020 |
Why?
| | Flavoproteins | 1 | 2006 | 8 | 0.020 |
Why?
| | ARNTL Transcription Factors | 1 | 2006 | 17 | 0.010 |
Why?
| | 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 1 | 2005 | 1 | 0.010 |
Why?
| | Quinpirole | 1 | 2005 | 10 | 0.010 |
Why?
| | Photoperiod | 1 | 2006 | 55 | 0.010 |
Why?
| | Kainic Acid | 1 | 2005 | 33 | 0.010 |
Why?
| | Microscopy, Confocal | 1 | 2007 | 319 | 0.010 |
Why?
| | Cryptochromes | 1 | 2006 | 25 | 0.010 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2007 | 154 | 0.010 |
Why?
| | Excitatory Amino Acid Agonists | 1 | 2005 | 42 | 0.010 |
Why?
| | Cell Nucleus | 1 | 2009 | 588 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2006 | 166 | 0.010 |
Why?
| | Rats, Inbred F344 | 1 | 2005 | 268 | 0.010 |
Why?
| | Receptors, Dopamine D2 | 1 | 2005 | 93 | 0.010 |
Why?
| | Adolescent | 1 | 2024 | 22530 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2010 | 2524 | 0.010 |
Why?
| | Calcium Signaling | 1 | 2006 | 245 | 0.010 |
Why?
| | Animals, Newborn | 1 | 2007 | 891 | 0.010 |
Why?
| | Physical Conditioning, Animal | 1 | 2006 | 242 | 0.010 |
Why?
| | Prospective Studies | 1 | 2015 | 8057 | 0.010 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 2001 | 24 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 2028 | 0.010 |
Why?
| | Injections, Subcutaneous | 1 | 2001 | 170 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1476 | 0.010 |
Why?
| | Prodrugs | 1 | 2001 | 52 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2006 | 1164 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2001 | 782 | 0.010 |
Why?
| | Aging | 1 | 2009 | 1969 | 0.010 |
Why?
| | Reactive Oxygen Species | 1 | 2001 | 611 | 0.010 |
Why?
| | Intestines | 1 | 2001 | 354 | 0.010 |
Why?
| | Brain | 1 | 2010 | 2947 | 0.010 |
Why?
| | Time Factors | 1 | 2005 | 7123 | 0.010 |
Why?
|
|
Pozdeyev's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|